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Transcriptome Profiling of Spinal Muscular Atrophy
Motor Neurons Derived from Mouse Embryonic Stem
Cells
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Abstract
Proximal spinal muscular atrophy (SMA) is an early onset, autosomal recessive motor neuron disease caused by loss of or
mutation in SMN1 (survival motor neuron 1). Despite understanding the genetic basis underlying this disease, it is still not
known why motor neurons (MNs) are selectively affected by the loss of the ubiquitously expressed SMN protein. Using a
mouse embryonic stem cell (mESC) model for severe SMA, the RNA transcript profiles (transcriptomes) between control and
severe SMA (SMN2+/+;mSmn2/2) mESC-derived MNs were compared in this study using massively parallel RNA sequencing
(RNA-Seq). The MN differentiation efficiencies between control and severe SMA mESCs were similar. RNA-Seq analysis
identified 3,094 upregulated and 6,964 downregulated transcripts in SMA mESC-derived MNs when compared against
control cells. Pathway and network analysis of the differentially expressed RNA transcripts showed that pluripotency and cell
proliferation transcripts were significantly increased in SMA MNs while transcripts related to neuronal development and
activity were reduced. The differential expression of selected transcripts such as Crabp1, Crabp2 and Nkx2.2 was validated in
a second mESC model for SMA as well as in the spinal cords of low copy SMN2 severe SMA mice. Furthermore, the levels of
these selected transcripts were restored in high copy SMN2 rescue mouse spinal cords when compared against low copy
SMN2 severe SMA mice. These findings suggest that SMN deficiency affects processes critical for normal development and
maintenance of MNs.
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80–90%) of SMN2 mRNAs to lack exon 7 (SMND7). SMND7 is
not fully functional and prone to degradation [11,12]. SMN2 can,
however, provide some fully functional SMN protein. The copy
number of SMN2 modifies the severity of SMA phenotype in
humans [13–20]. Although the genetics underlying SMA are
known, the mechanisms leading to the disease are poorly
understood.
SMN is a ubiquitously expressed protein that facilitates the
assembly of ribonucleoproteins (RNPs) [21]. The assembly of Utype small nuclear RNPs (snRNPs) is developmentally regulated in
many cell types [22]. Knockdown of snRNP assembly in zebrafish
results in degeneration of motor neuron axons [23]. snRNP
assembly is defective in SMN-deficient SMA cells [24]. However,
this function of SMN in U-type snRNP assembly is required by all

Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive, earlyonset neurodegenerative disorder characterized by the degeneration of a-motor neurons (MNs) in the anterior horn of the spinal
cord which leads to progressive muscle weakness and atrophy [1].
SMA is a leading genetic cause of infant death worldwide with 1 in
5000–10,000 children born with the disease [2,3] and a carrier
frequency of 1:25–50 [4–7]. SMA results from the loss or mutation
of the SMN1 (survival motor neuron 1) gene on chromosome
5q13 [8]. There is an inverted duplication of SMN1 in humans
called SMN2 [9,10]. The duplication of SMN1 only occurs in
humans. Within SMN2, there is a C-to-T transition in an exonic
splice enhancer of exon 7 that results in the vast majority (about
PLOS ONE | www.plosone.org
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were found to generate action potentials and developed axons and
synapses when co-cultured with muscle cells [38]. mESC lines
have been established for low copy SMN2 severe SMA mice also
harboring a MN-specific reporter construct (HB9:eGFP) [39].
When these SMA mESCs are directed to differentiate into MNs,
they start dying after the differentiation process [39]. MNs derived
from SMA mESCs can, therefore, potentially provide important
insights into the pathogenesis of SMA.
In this study, we will use cultured MNs derived from SMA
mESCs to determine how reduced levels of the ubiquitously
expressed protein SMN result in selective MN death in SMA.
Previous studies have used cDNA microarrays to identify
differentially expressed mRNAs in SMA mouse whole spinal
cords and in primary MN cultures [40–42]. Microarrays can only
identify known RNA transcripts which limits their utility for
comprehensively characterizing transcriptomes. Massively parallel
RNA sequencing, commonly known as RNA-Seq [43], is a
recently developed deep-sequencing technology used for transcriptome profiling [44]. RNA-Seq directly reads the sequences of
the cDNA pool which results in a very low background signal as
compared to the indirect method of measuring hybridization
intensity used in microarray analysis. Since RNA-Seq directly
reads cDNA sequences, novel transcripts and isoforms can be
identified. In this study, we use RNA-Seq to annotate and
compare the transcriptome profile of MNs derived from severe
SMA mESCs with those derived from normal mESCs. Analysis of
over-represented biological pathways and networks revealed that
SMA mESC-derived MNs have increased expression of RNA
transcripts related to pluripotency and reduced expression of
neuronal development and function RNA transcripts. This study
provides new insights into the molecular consequences of SMN
deficiency in MNs and identifies novel targets for the development
of neuroprotective therapeutics.

cells. So why are MNs primarily affected in SMA given this
ubiquitous function? Gabanella et al. show that snRNP assembly is
defective in tissues from mouse models for SMA and that the
extent of reduced snRNP assembly correlates with phenotypic
severity of these SMA mice [22]. Furthermore, snRNP assembly is
more markedly affected by Smn deficiency in SMA mouse neural
tissues than in other tissues like the kidney. This enhanced
sensitivity of neurons to deficits in snRNP assembly may explain
why MNs are primarily affected in SMA.
In addition to its role in snRNP biogenesis, SMN may also have
functions which are unique to MNs. SMN associates with
cytoskeletal elements in MN dendrites and axons within the rat
spinal cord [25]. Knockdown of Smn expression in zebrafish
embryos using morpholino antisense oligonucleotides leads to
reduced axonal outgrowth and axonal pathfinding defects [26].
Ectopic overexpression of wild-type SMN in these Smn-knocked
down zebrafish embryos restores normal axonal growth and
pathfinding. Moreover, axonal defects in Smn-knocked down
zebrafish embryos are corrected by overexpression of mutant
SMNs which are incapable of snRNP assembly [27]. The core
protein components of snRNPs, the Sm proteins, do not colocalize
with SMN in neuronal processes [28]. Taken together, these
observations suggest that SMN may have a unique function in
neurons that is independent of snRNP biogenesis. Several studies
have suggested that SMN may play a role in axonal trafficking.
SMN has been shown to interact with the heterogeneous nuclear
ribonucleoprotein-R (hnRNP-R) [29]. hnRNP-R binds to the 39untranslated region (39-UTR) of b-actin mRNA [30]. Transport of
b-actin mRNA and protein into growth cones has been shown to
be essential in developing neurites [31]. Reduced expression of
Smn in mouse MNs results in reduced axonal outgrowth and
trafficking of b-actin mRNA along axons [30]. Conditional
knockout of b-actin in mouse MNs, however, does not affect the
morphologies of MN neurites suggesting that b-actin mRNA
transport along axons may not be essential for MN axon
development [32]. Although neuron-specific roles of SMN have
been proposed, further studies are needed to determine how these
neuron-specific roles are involved in the pathogenesis of SMA.
Mouse models have been instrumental in studying the function
of SMN and how this function is disrupted in SMA. Mice, like all
animals except humans, have only one SMN gene (mSmn) that is
equivalent to SMN1. Homozygous disruption of mSmn in mice is
embryonically lethal [33]. Transgenic overexpression of SMN2
rescues the embryonic lethality of mSmn deficiency [34,35]. mSmn
nullizygous mice that also harbor few copies of the SMN2
transgene (i.e. 1 or 2) develop a severe motor phenotype
resembling SMA and die within 7 days after birth [34,35].
Increasing the SMN2 copy number in these mSmn nullizygous
mice improves the survival and phenotype of these SMA mice; in
fact, expression of 8–16 copies of SMN2 fully rescues the SMA
phenotype in these mice [34,36]. Patients who have been
identified genetically as SMA—i.e. loss of SMN1—are phenotypically normal when they carry at least 5 copies of SMN2 [16].
Thus, SMN2 expression modifies the phenotypic severity of SMA
in mice as well as in man and makes SMN2 a target for the
development of SMA therapeutics.
The low copy SMN2 SMA mouse phenotypically resembles
type I SMA in humans [34]. The short lifespan as well as the low
frequency of pups that survive past birth limit their use for
mechanistic studies; therefore, an in vitro model would be useful
for such studies. Murine embryonic stem cells (mESCs) are able to
differentiate into spinal neural progenitor cells and then into MNs
through exposure to the morphogens retinoic acid (RA) and Sonic
hedgehog (Shh) [37]. Motor neurons differentiated from mESCs
PLOS ONE | www.plosone.org

Materials and Methods
Ethics Statement
All animal experiments were conducted in accordance with the
protocols described in the National Institutes of Health Guide for
the Care and Use of Animals and were approved by the Nemours
Biomedical Research Institutional Animal Care and Use Committee.

Embryonic Stem Cell Culture
Two different types of mESC lines were used for these
experiments. The first set of mESC lines—Hb9 and A2—were
provided by Dr. Lee L. Rubin and were derived from either wild-type
(SMN2+/+;mSmn+/+) or SMA (SMN2+/+;mSmn2/2) mice expressing
the HB9:eGFP reporter construct [39]. The mice used to establish
these mESC lines were generated by interbreeding the low-copy
SMN2 carrier mouse (FVB.Cg-Tg(SMN2)89AhmbSmntm1Msd/J)
with HB9:eGFP (mHB9:Gfp1b) transgenic mouse [37,45]. The
second set of mESC lines—C4 and E2—were provided by Dr.
Douglas Kerr [46]. These lines were derived from wild-type and
SMA mice, respectively, and do not harbor a motor neuron-specific
marker gene.
mESCs were grown as previously described [46,47]. Briefly,
mESCs were grown on a primary mouse embryonic fibroblast
feeder layer (Millipore, Billerica, MA, USA) in 10 cm tissue
culture dishes. Cells were cultured with medium containing
DMEM supplemented with 15% fetal bovine serum (Stem Cell
Technologies, Vancouver, BC, Canada), 1% GlutaMax-I (Life
Technologies, Carlsbad, CA, USA), 1% MEM non-essential
amino acids (Millipore), 1% nucleosides (Millipore), 0.1 mM
2
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b-mercaptoethanol (Millipore), 1% penicillin/streptomycin (Life
Technologies) and 10 ng/mL murine leukemia inhibitory factor
(LIF; Millipore).

ES Cell Differentiation into MNs
mESCs were differentiated into motor neurons (MNs) as
outlined in Figure 1 [46,47]. Briefly, mESCs were dissociated
with 0.25% trypsin/EDTA and placed into a T75 cell culture flask
coated with 0.1% gelatin (Stem Cell Technologies). Fibroblasts
were allowed to re-attach to the flask. The floating mESCs were
collected and plated into a 10 cm petri dish containing 10 mL of
Neural Differentiation Medium (DMEM supplemented with 15%
FBS, 1% nonessential amino acids, 1% GlutaMax-I, 1%
penicillin/streptomycin, 1 mM monothioglycerol (Sigma-Aldrich),
50ng/ml noggin (Life Technologies), 20 ng/mL basic fibroblast
growth factor (FGF2; Life Technologies) and 20 ng/mL fibroblast
growth factor-8b (FGF-8b; Life Technologies)). Media was
replaced daily. After two days, embryoid bodies (EBs) were resuspended in MN differentiation medium (NITSf; basal medium A
(Stem Cell Technologies) supplemented with 10% Knockout SR
(serum replacement; Life Technologies), 1% N-2 supplement (Life
Technologies), 1% ITS-B supplement (Stem Cell Technologies),
1% ascorbic acid (Stem Cell Technologies), 1% penicillin/
streptomycin, 0.1% mM b-mercaptoethanol, 0.5% GlutaMax-I,
30% D-glucose (Sigma-Aldrich), 20 mg/mL heparin (SigmaAldrich) and 50 mg/mL fibronectin (Stem Cell Technologies)) in
the presence of 1 mM RA (Sigma-Aldrich) and 1 mM Smoothened
agonist (SAG; Millipore). Media was replaced daily for 5 days
when EBs were collected, washed with phosphate-buffered saline
(PBS) and dissociated in Accumax (Millipore). Cell aggregates
were filtered through a BD cell strainer and single cells were then
suspended in NITSf medium supplemented with 10 ng/mL each
of brain-derived neurotrophic factor (BDNF; R&D Systems), glial
cell-derived neurotrophic factor (GDNF; R&D Systems), ciliary
neurotrophic factor (CNTF; R&D Systems) and neurotrophin-3
(NT-3; R&D Systems). The cells were plated at a concentration of
16105 cells per well in a 24 well plate that contained coverslips
coated with 100 mg/mL poly-DL-ornithine hydrobromide (SigmaAldrich), 2 mg/mL laminin (Millipore) and 300 mg/mL Matrigel
Matrix Basement Membrane (BD Bioscience, San Jose, CA, USA).

Figure 1. Outline for the differentiation of mouse embryonic
stem cells (mESCs) into motor neurons (MNs). mESCs were first
converted into neuron-primed embryoid bodies (EBs) by treatment with
noggin, fibroblast growth factor 2 (FGF2) and FGF8b for 2 days. The
neuron-primed EBs were then directed to differentiate into MN spheres
by treatment with retinoic acid (RA) and Smoothened agonist (SAG) for
5 days. The MNs were then dissociated from the spheres and then
either isolated using fluorescence-activated cell sorting (FACS) for
subsequent RNA isolation or allowed to mature for 3 days with a MN
maturation cocktail containing brain-derived neurotrophic factor
(BDNF), glial cell-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF) and neurotrophin-3 (NT3).
doi:10.1371/journal.pone.0106818.g001

for genotyping. All embryonic and postnatal samples were
genotyped as described previously [34,48].

Immunofluorescence
Cells grown on coverslips were washed with PBS. Cells were
fixed with 4% paraformaldehyde (Sigma-Aldrich) in PBS for
20 min. Cells were rinsed with PBS+ (0.1% saponin (SigmaAldrich) and 0.02% NaN3 (Sigma-Aldrich) in PBS, pH 7.4) and
blocked with PBS+BSA (20 mg/mL bovine serum albumin (BSA;
Sigma-Aldrich) in PBS+) for 30 min. Cells were then incubated
overnight at 4uC with mouse anti-Hb9 (1:10; clone 81.5C10,
Developmental Studies Hybridoma Bank (DSHB), Iowa City, IA,
USA), mouse anti-Tuj1 (1:1000; Covance, Princeton, NJ, USA),
mouse anti-Islet-1 (1:50; clone 40.2D6, DSHB), mouse anti-nestin
(1:500, Millipore), or mouse anti-NeuN (1:200, Millipore) in PBS+
BSA supplemented with rabbit anti-GFP (1:2000, Rockland
Immunochemicals, Gilbertsville, PA, USA). After three washes
with PBS+, cells were incubated for 1 hr at room temperature with
Alexa Fluor 594 goat anti-mouse IgG (Life Technologies) and
Alexa Fluor 488 goat anti-rabbit IgG (Life Technologies) in PBS+
BSA. Cells were washed three times with PBS+ and incubated
with 100 ng/mL Hoechst 33342 (Life Technologies) in ddH2O for
10 min and rinsed with ddH2O before mounting in Immu-Mount
(Shandon-Lipshaw). Images were obtained using a Leica TCS SP5
confocal microscope.

Animals
Spinal cords were collected from two different mouse models for
SMA: the severe low copy SMN2 SMA (SMN2(Ahmb89)+/
+
;mSmn2/2)
and
the
high
copy
SMN2
rescue
(SMN2(Ahmb(566)+/+;mSmn2/2) mice [34]. Both mouse lines
are available from Jackson Laboratories (Bar Harbor, ME; stock
numbers 005024 and 008026, respectively). To obtain low copy
SMN2 SMA mice, carrier mice ((SMN2(Ahmb89)+/+;mSmn+/2)
were interbred to generate SMA, carrier and control
(SMN2(Ahmb89)+/+;mSmn+/+) progeny. Since the high copy
SMN2 rescue mice are phenotypically normal [34], the necessary
mice were generated from interbreeding rescue mice.
Spinal cords were collected at 2 time points: embryonic day
13.5 (e13.5) and postnatal day 3 (PND03; with the day of birth
being defined as PND01). For collecting e13.5 samples, timedpregnant dams (as assessed by the presence of a vaginal plug) were
euthanized at e1360.5 and the spinal cords were rapidly dissected
from the embryos, snap-frozen and stored at 280uC until RNA
isolation. Additional tissues were harvested from each embryo for
genotyping. For postnatal samples, pups were euthanized and the
spinal cords were rapidly dissected from the pups, snap-frozen and
stored at 280uC until RNA isolation. Tail biopsies were also taken
PLOS ONE | www.plosone.org

Immunoblot Analysis
Cells were pelleted and lysed in a lysis buffer containing 20 mM
Tris-HCl, pH 7.4, 150 mM sodium chloride (NaCl), 1% Triton
X-100, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM
ethylene glycol-bis(2-aminoethylether)-N,N,N9,N9-tetraacetic acid
(EGTA), 1 mM sodium glycerolphosphate, 2.5 mM sodium
pyrophosphate, 100 mM sodium fluoride (NaF), 10% glycerol,
3
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Gene Expression Omnibus (GEO) [49] under accession number
GSE56284.

1 mM sodium orthovanadate, 1 mM phenylmethylsulfonylfluoride (PMSF), 5 mg/mL aprotinin and 2 mg/mL leupeptin. The
lysates were sonicated and centrifuged at 13,200 rpm for 15 min.
Protein concentration of the supernatants were analyzed with
Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL,
USA). 50 mg of protein per lane were electrophoretically separated
in a 10% polyacrylamide gel containing 0.1% SDS and transferred
onto a Hybond-P PVDF membrane (GE Healthcare, Piscataway,
NJ, USA). The blots were blocked in 5% nonfat milk in Trisbuffered saline with 0.1% Tween-20 (TBS-T) for 1 hr. The blots
were then incubated overnight at 4uC with mouse anti-SMN
antibody (1:5000, BD Biosciences) diluted in 3% BSA in TBS-T.
The blots were then washed three times with TBS-T and then
incubated for 1 hr with horseradish peroxidase (HRP)-conjugated
sheep anti-mouse IgG (1:2500, GE Healthcare) diluted in 3% BSA
in TBS-T. The protein on the membrane was detected using a
chemiluminescence buffer containing 1.25 mM luminol (SigmaAldrich), 198 mM p-coumaric acid (Sigma-Aldrich) and 0.00915%
H2O2 (Sigma-Aldrich) in 100 mM Tris-HCl, pH 8.5. The
membrane was then stripped with Re-Blot Plus Strong Solution
(Millipore) and reprobed using rabbit anti-glyceraldehyde-3phosphate dehydrogenase (GAPDH; 1:20,000, Sigma-Aldrich) as
primary antibody and HRP-conjugated goat anti-rabbit IgG
(1:2500, Rockland Immunochemicals) as secondary antibody.

RNA-Seq Data Analysis
RNA-Seq reads were assessed for quality control with FastQC
(version 0.10.1; Babraham Bioinformatics, Cambridge, UK).
Adapter sequences and poly-A tails were removed from sequencing reads with CutAdapt (MIT, Cambridge, MA) [50] and were
confirmed by FastQC. Reads were mapped to a reference mouse
transcriptome and genome (NCBI m37) using TopHat (version
2.04; [51]). The reference genome and annotation was obtained
from Ensembl (http://www.ensembl.org). Transcripts were assembled and transcript abundances were measured as fragments
per kilobase of exon per million fragments mapped (FPKM) by
Cufflinks [52]. Cuffdiff [53] was then used to determine
differential expression. Differential expressed genes were plotted
using the R package CummeRbund [53].

Gene Pathways and Networks Analysis
Identification of biological pathways and networks affected by
Smn deficiency in mESC-derived MNs was completed using
Ingenuity Pathway Analysis (IPA build version 261899; Ingenuity
Systems, Inc., Redwood City, CA). The list of differentially
expressed transcripts generated from Cuffdiff was divided into
upregulated and downregulated lists of transcripts and were
imported into IPA. Biological function and canonical pathways
were determined to be over-represented using the Fisher exact test
with a false discovery rate (FDR) correction (p#0.05). A set of
interacting biological networks was generated in IPA from the
upregulated and downregulated transcript lists. A network score
was computed based on the likelihood that the focus transcripts
specifically belong to this network as opposed to being in the
network by chance. Based on other published work [54], only
those networks with scores greater than or equal to 15 were
considered relevant for further analysis.
The Upstream Regulator Analysis (URA) algorithm of IPA
allows for the identification of upstream regulators—transcription
factors, signaling molecules and drugs—which can affect gene
expression [55]. URA was completed on upregulated and
downregulated transcripts and list of putative upstream regulators
was provided. Each upstream regulator was assigned an activation
z-score; upstream regulators were considered as being activated or
inhibited if their activation z-scores were either greater than or
equal to 2.0 for activated regulators or less than or equal to 22.0
for inhibited regulators.

Fluorescence-Activated Cell Sorting
Dissociated ES cells were filtered through a cell strainer,
suspended in DMEM with 20 mg/mL of propidium iodide (PI)
and sorted using a 488 nm laser attached to either a MoFlo cell
sorter (Coulter; Kimmel Cancer Center, Thomas Jefferson
University) or the FACSAria II sorter (BD Biosciences; Center
for Translational Cancer Research, University of Delaware). Cells
were passed through a 100 mm nozzle tip at a speed of
approximately 12,500 events per second. Embryonic stem cells
from nonGFP-expressing, wild-type mice described previously
[46] were used as a negative control to set the cutoff for
background fluorescence. Cells that were GFP positive, PI
negative were collected in a 5 mL round bottom test tube (BD
Biosciences, Franklin Lakes, NJ, USA) with PBS supplemented
with 60% FBS. Approximately a million cells were collected per
sample. Sorted cells were centrifuged, PBS was removed and
pellets were snap frozen for RNA isolation.

RNA Isolation
Total RNA was isolated from cells using the RNeasy mini kit
(QIAGEN, Germantown, MD, USA) with an additional DNase I
(QIAGEN) digestion step to remove any genomic DNA contamination. The concentration of the purified RNA was determined
by a ND-1000 NanoDrop the spectrophotometer (NanoDrop
Technologies, Wilmington, DE). RNA integrity was assessed by
the Agilent Technologies 2100 Bioanalyzer.

cDNA Synthesis and Quantitative Reverse TranscriptasePolymerase Chain Reaction (qRT-PCR)
cDNA was prepared from 0.5–1 mg total RNA using the iScript
cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) as per
manufacturer’s instructions. The cDNA—diluted 200–400 fold—
was amplified via RT-PCR using the QuantiTect SYBR Green
PCR kit (QIAGEN). The target primers listed in Table 1 were
synthesized by Integrated DNA Technologies (Coralville, IA) and
primers for the reference transcripts b-glucuronidase (Gusb),
phosphoglycerate kinase 1 (Pgk1) and ribosomal protein L13a
(Rpl13a) were purchased from Real Time Primers LLC (Elkins
Park, PA). Quantitative PCR was performed in a 384 well plate on
a 7900 HT Fast Real-Time PCR system (Applied Biosystems,
Foster City, CA). Each sample was assayed in triplicate. Relative
transcript levels were calculated using the comparative Ct (22DDCt)
method [56] where DCt is defined as the difference between the Ct
for the target transcript and the Ct for the geometric mean of

RNA-Seq
1 mg of RNA from each sample (n = 3/genotype) was collected
and sent to the Sequencing and Genotyping Center at the
Delaware Biotechnology Institute in the University of Delaware
for RNA-Seq library preparation and sequencing. The cDNA
library was prepared using the TruSeq RNA Sample Prep Kit
(Illumina, San Diego, CA) according to the manufacturer’s
directions. The samples were then clustered and sequenced on
an Illumina HiSeq 2500. Deep sequencing was performed on
triplicates for each cell line (total six samples) for a 50 cycle single
end run. The raw sequence data have been deposited in the NCBI
PLOS ONE | www.plosone.org
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Table 1. Sequences of primers used for qRT-PCR.

Gene Name

Primers (59-.39)

Ampicon size (bp)

Crabp1

(F) CTTCAAGGTCGGAGAGG (R) GGAACAAGCTGGCCACC

238

Crabp2

(F) GGAGATTAACTTCAAGATCGGGGA (R) GCTAGTTTGTAAGATGGACGTGGG

321

Isl1

(F) CGGAGAGACATGATGGTGGTT (R) GGCTGATCTATGTCGCTTTGC

109

Nkx2.2

(F) CCTCCCCGAGTGGCAGAT (R) GAGTTCTATCCTCTCCAAAAGTTCAAA

74

Pla2g1b

(F) CAGGCGCTGCTGCACACAG (R) GTCTAAGTCGTCCACTGGGGTGC

158

Smn1

(F) TGCTCCGTGGACCTCATTTCTT (R) TGGCTTTCCTGGTCCTAATCCTGA

70

Vim

(F) GAATGACCGCTTTGCCAACTACAT (R) GCTTCCTCTCTCTGGAGCATCTCCT

267

Gusb

(F) AATGAGCCTTCCTCTGCTCT (R) AACTGGCTATTCAGCTGTGG

227

Rpl13a

(F) ATGACAAGAAAAAGCGGATG (R) CTTTTCTGCCTGTTTCCGTA

215

Pgk1

(F) GCAGATTGTTTGGAATGGTC (R) TGCTCACATGGCTGACTTTA

185

doi:10.1371/journal.pone.0106818.t001

Gusb, Pgk1 and Rpl13a [57] and DDCt is defined as the difference
between the DCt for the SMA sample and the DCt for the control
sample.

differentiated Hb9 and A2 cells expressed MN specific markers
Hb-9 and Islet-1 (Figure 4B) [58,59]. One noticeable difference
was the number of GFP+ neuron-like cells present on coverslips
after plating and growing for 3 days. Coverslips with differentiated
Hb9 cells had an abundance of GFP+ cells whereas there were
very few neuron-like GFP+ cells on coverslips from A2 SMA cells.
This reduced viability of SMA mESC-derived MNs was consistent
with a previous report [39]. Thus, both the control and SMA
mESCs can be directed to differentiate into MNs and SMNdeficient SMA MNs are less viable than control MNs derived from
mESCs.

Statistical Analysis
All quantitative data is expressed as mean 6 standard error. For
differential expression of RNA transcripts analyzed by RNA-Seq,
statistical analysis was completed using Cuffdiff and CummeRbund [53]. Statistical analysis for pathways and networks analysis
was completed by IPA. Statistical analyses of quantitative data
were completed using SPSS v.22.

Results
Control and SMA mESCs Differentiate into Motor
Neurons in vitro
Motor neurons (MNs) were generated from HB9:eGFPexpressing control (SMN2+/+;mSmn+/+, Hb9) and SMA (SMN2+/
+
;mSmn2/2, A2) mESCs using a combination of growth factors
and morphogens [47] as outlined in Figure 1. We first examined
the effect of MN differentiation of the levels total SMN protein
levels (mSmn and the SMN2 transgene) in Hb9 and A2 cells. Total
SMN protein levels were indeed reduced in undifferentiated as
well as in differentiated A2 cells relative to Hb9 cells (Figure 2).
The total SMN protein levels were similar between undifferentiated and differentiated Hb9 as well as for A2 cells; the
differentiation conditions thus do not affect total SMN protein
expression.
We next determined the effect of SMN deficiency on the
differentiation potential of mESCs into MNs. FACS analysis
showed the differentiation efficiency of viable control Hb9 cells
(Figure 3B; 17.766.1%) was similar to that observed in viable A2
SMA cells (Figure 3C; 16.363.2%). Reduced expression of SMN
similar to that observed in SMA does not affect the ability of
mESCs to differentiate into MNs.
To show that the differentiated cells from Hb9 and A2 mESCs
were morphologically MNs, these mESCs were directed to
differentiate into MNs and then plated in the presence of
neurotrophic factors to induce axonal growth and arborization
(Figure 1). The GFP+ Hb9 (control in Figure 4) and A2 (SMA
in Figure 4) cells were characterized using various neuronal
markers to test their MN identity. The presence of b-III tubulin
(Tuj1), a neuron-specific tubulin isoform, as well as post-mitotic
neuronal marker NeuN (also known as Fox-3) confirmed that the
GFP+ cells were indeed neurons (Figure 4A). As expected,
PLOS ONE | www.plosone.org

Figure 2. Expression of total SMN protein in undifferentiated
as well as MN-differentiated control and SMA cells. Representative immunoblots of both differentiated and undifferentiated mESCs
revealed a significantly reduced protein expression of SMN in A2 SMA
cell lines compared to Hb9 control cells. SMN levels were normalized to
Gapdh. C = control, S = SMA. Asterisks indicate significant differences
compared to controls (*p,0.05, Student’s t test).
doi:10.1371/journal.pone.0106818.g002

5

September 2014 | Volume 9 | Issue 9 | e106818

RNA-Seq of SMA Mouse Motor Neurons

Figure 3. Efficiency of differentiation of Hb9 control and A2 SMA mESCs into MNs. Differentiated cells were analyzed and sorted using
flow cytometry. Representative dot plots are shown. Cells treated with PI alone were used as a control (A). The proportion of MNs in the Hb9 control
(B) and A2 SMA (C) mESCs upon differentiation is similar.
doi:10.1371/journal.pone.0106818.g003

(Table 2); between 69% and 76% of reads were uniquely mapped
to the reference genome. The difference in the average number of
reads between Hb9 and A2 MNs samples was not statistically
significant (p = 0.22). Transcripts were assembled and transcript
abundance measured in FPKM; the expression levels for each
transcript were then compared between Hb9 and A2 MNs. The
distributions of transcript abundances—as measured in fragments
per kilobase of exon per million fragments mapped (FPKM)—
were different between A2 SMA and Hb9 control MNs
(Figure 5B). Overall, there were 41,945 expressed transcripts in
both Hb9 and A2 MNs of which 10,058 transcripts were found to
be differentially expressed in Hb9 and A2 MNs (p,0.05). Out of
the 10,058 statistically significant differentially expressed transcripts, 3094 were upregulated in A2 SMA samples compared to

Analysis of RNA-Seq Data from Control and SMA mESCDerived MNs
Whole transcriptome differential expression between FACScollected Hb9 and A2 MNs was completed using massively
parallel RNA sequencing (RNA-Seq). The total number of reads
produced from each sample (n = 3/genotype) was around 100
million reads per sample. The quality of the trimmed reads—as
assessed with FastQC—was very high in that the sequence quality
had a Phred score of around 39 and an average base Phred quality
score was around 32. As a point of reference, a Phred quality score
of 30 corresponds to a base call accuracy of 99.9%.
The trimmed sequencing reads were then mapped to the mouse
reference genome (Figure 5A). The total number of mapped
reads per sample ranged between 29,763,880 and 44,570,352

PLOS ONE | www.plosone.org
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Figure 4. Immunofluorescent characterization of mESC derived control and SMA MNs. Hb9 control and A2 SMA mESCs were directed to
differentiate into MNs, dissociated and then grown on coated coverslips in the presence of neurotrophic factors for 3 days. Cells were then
immunostained with antibodies against GFP (green) and either (A) the panneuronal markers Tuj1 (b3-tubulin) or NeuN (Fox3) or (B) the MN-specific
markers Hb9 and Islet 1 (red). Nuclei were counterstained with Hoescht 33342 (blue). The scale bar represents 25 mm.
doi:10.1371/journal.pone.0106818.g004

Hb9 control and 6964 were downregulated (Figure 5C). A list of
differentially expressed RNA transcripts is provided in Table S1.
Since the A2 SMA cells are homozygous for the targeted
deletion of mSmn (Smn1), the levels of Smn1 mRNA is expected to
be lower in A2 SMA MNs. Indeed, the level of Smn1 mRNA was
reduced by 4.7-fold in A2 SMA MNs when compared to Hb9
controls MNs (Table S1). The mRNA transcript data (RNA-Seq)
and the protein results (Smn immunoblot in Figure 2) were
consistent. Interestingly, Hb9 (Mnx1) transcripts levels were not
significantly different between A2 and Hb9 MNs. This observation
was supported by the FACS analysis in Figure 3.
PLOS ONE | www.plosone.org

Pathway and Network Analysis of Differentially Expressed
Transcripts in SMA ESC-derived MNs
Ingenuity Pathway Analysis (IPA) was used to determine the
biological relevance of the differentially expressed transcripts
between A2 SMA and Hb9 control mESC-derived MNs. IPA uses
the Ingenuity Knowledge Base, which is a manually curated
repository of literature-based biological and pharmacological data
(www.ingenuity.com) [55]. 77 biological functions were overrepresented (with a Fisher’s exact test p-value cutoff of 0.05) using the
list of transcripts upregulated in A2 SMA MNs, the 7 highest
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Figure 5. RNA-Seq-identified differentially expressed transcripts between mESC-derived Hb9 control and A2 SMA MNs. (A)
Flowchart outlining the analysis of RNA sequencing data. The programs used for each step are shown to the right of the flowchart. (B) Area plot
showing the distributions of FPKM values of significant transcripts in Hb9 control (blue) and A2 SMA (orange) MNs. (C) A volcano plot showing the
log2-fold difference of statistically significant (p = 0.05) transcripts (shown in blue) between Hb9 control and A2 SMA MNs.
doi:10.1371/journal.pone.0106818.g005

scoring entries are shown in Figure 6A. Many of these highest
scoring entries are related to developmental functions. In the
downregulated transcripts, there were 62 overrepresented biological functions (Figure 6B) with many of these highest scoring
functions involving nervous system development and disease.
We also used IPA to identify canonical pathways that were
overrepresented in the lists of transcripts either upregulated or
downregulated in A2 SMA MNs. Most of the highest scoring
overrepresented canonical pathways (6 out of 14) from the
upregulated transcripts were related to ESC pluripotency
(Figure 6C with the top canonical pathway, Transcriptional
Regulatory Networks in ESCs, shown in detail in Figure 6E).
Many of the highest scoring canonical pathways identified from
the list of downregulated transcripts (5 out of 19) were involved
with nervous system development (Figure 6D). In fact, the top
downregulated canonical pathway is Notch signaling (shown in
detail in Figure 6F).
In addition to identify biological functions and canonical
pathways altered as a result of SMN deficiency in MNs, IPA
can also integrate these functions and pathways to identify

functionally interacting gene networks, or interactomes. We
analyzed our lists of transcripts upregulated or downregulated in
A2 SMA MNs for overrepresented interactomes. IPA network
scores greater than or equal to 15 were considered significant [54].
Using these criteria, there were 2 significant interactomes
identified from analysis of the upregulated transcripts and 13
from analysis of the downregulated transcripts. The top upregulated interactome (score of 59; Figure 7A) contained many gene
products involved in ESC pluripotency and cellular development,
growth and proliferation. Gene products with roles in nervous
system development and function were present in the top scoring
interactome of the downregulated transcripts (score of 60;
Figure 7B). Taken together, a systems biology-based comparison
of A2 SMA and Hb9 control mESC-derived MNs shows that
functions, pathways and gene networks involved in pluripotency
are upregulated in SMA MNs while those involved in nervous
system development and function are downregulated in SMA
MNs.

Table 2. RNA-Seq reads mapped to NCBI mouse genome build 37 using TopHat.

Control

SMA

Sample 1

Sample 2

Sample 3

Sample 1

Sample 2

Sample 3

Total Reads

29,763,880

14,863,496

36,877,629

37,203,080

32,327,505

44,570,352

Reads Removed

23.86%

22.74%

23.65%

29.20%

28.81%

28.16%

Reads Mapped

74.49%

75.50%

74.88%

69.33%

69.67%

70.60%

doi:10.1371/journal.pone.0106818.t002
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Figure 6. Gene network analysis of differentially expressed transcripts between mESC-derived Hb9 control and A2 SMA MNs.
Ingenuity Pathways Analysis (IPA) of biological functions for transcripts (A) upregulated or (B) downregulated in A2 SMA MNs compared to Hb9
control MNs. IPA of canonical pathways for transcripts (C) upregulated or (D) downregulated in A2 SMA MNs compared to Hb9 control MNs. IPA was
performed on upregulated or downregulated transcripts with at least a 2-fold change and a p value less than or equal to 0.05. The top 7 canonical
pathways or biological functions were shown in the bar graphs. The top canonical pathway for (E) upregulated (Transcriptional Networks in ESCs) or
(F) downregulated (Notch Signaling) transcripts in A2 SMA MNs compared to Hb9 control MNs. Downregulated transcripts are green while the
upregulated transcripts are red.
doi:10.1371/journal.pone.0106818.g006

retinoic acid binding protein 1 (Crabp1), Crabp2, Islet-1 (Isl1),
NK2 homeobox 2 (Nkx2.2), phospholipase A2, group 1B (Pla2g1b)
and vimentin (Vim). The sample RNAs used for qRT-PCR (n = 3/
genotype) were not the same as those used for RNA-Seq so they
represent biological replicates as opposed to technical replicates
[60]. The differences in transcript levels between Hb9 and A2
MNs determined by qRT-PCR followed the same trends as those
determined by RNA-Seq although the magnitudes of change were
generally higher in the RNA-Seq data (Figure 9A). RNA-Seq is
more sensitive than qRT-PCR at detecting changes in transcript
levels.
We next determined if the changes in RNA levels observed in
these SMA mESC-derived MNs were unique to these specific cells.
Control and severe SMA mESCs that do not contain the HB9eGFP reporter transgene—C4 and E2 cells, respectively—[46]
were directed to differentiate into MNs. The extracted total RNAs
from C4 and E2 MNs were analyzed by qRT-PCR. As shown in
Figure 9B, with the exception of Nkx2.2, the changes in
transcript levels between C4 and E2 MNs were similar to those
observed between eGFP-labeled Hb9 and A2 MNs. One possible
explanation for this discrepancy in changes in Nkx2.2 levels is that
the MNs were not separated from other cell types after
differentiation of C4 and E2 mESCs.
Using two-dimensional differential in-gel electrophoresis (2DDIGE) and mass spectrometry, we previously identified a set of
proteins that are differentially expressed between control and
severe SMA mESC-derived MNs [46]. We compared this list of
differentially expressed proteins with our list of differentially
expressed mRNA transcripts. Of the 12 proteins identified, lactate
dehydrogenase B (Ldhb) and aldehyde dehydrogenase (Aldh5a1)
showed corresponding changes in mRNA levels between control
and SMA mESC-derived MNs (Table 3). 5 proteins that showed
significant difference in protein levels between control and SMA
mESC-derived MNs—brain creatine kinase (Ckb), tropomyosin 3
(Tpm3), ubiquitin C-terminal hydroxylase L1 (Uchl1), 14-3-3c
(Ywhag) and heat shock protein 90b (Hsp90b1)—did not exhibit
any corresponding changes in mRNA levels. While some genes
have similar changes in mRNA and protein expression in SMA
MNs relative to control MNs, there are other genes which are
differentially expressed at the protein level but not at the mRNA
level. These observations suggest that differential gene regulation
occurs at many levels—i.e. transcriptional vs. post-transcriptional—between SMA and control MNs.

In Silico Identification of Upstream Regulators in SMA
mESC-derived MNs
Using the Upstream Regulator Analysis (URA) component of
IPA, we can identify possible upstream regulatory molecules that
may be affecting changes in gene expression [55]. A list of such
upstream regulators was compiled by URA using the transcripts
which were upregulated or downregulated in A2 SMA mESCderived MNs. We divided these upstream regulators into 3 groups:
transcriptional regulators, signaling components and drugs. As
shown in Figure 8A, 4 transcriptional regulators were activated
in SMA MNs while 13 transcriptional regulators were inhibited in
SMA MNs. Of these 17 transcriptional regulators identified, the
transcript levels of only three—Pou5f1 (Oct-4), Nanog and
Ascl1—were significant altered in A2 SMA MNs (3.0-fold
increase, 2.5-fold increase and 5.6-fold decrease, respectively).
In addition to transcriptional upstream regulators, the intracellular effects of 18 signaling molecules were identified as being
significantly modified in A2 SMA MNs (Figure 8B). These
signaling molecules include growth factors and cytokines like
transforming growth factor b (TGFb) and neurotrophin-4 (NTF4), intracellular second messengers like cyclic AMP (cAMP) as well
as nuclear receptor ligands such as dihydrotesterone (DHT) and
tretinoin (RA). The effects of all of these signaling molecules except
for inhibin bA (INHBA) were attenuated in A2 SMA MNs. The
levels of Sonic hedgehog (Shh) mRNA were significantly reduced
(2.4-fold) in A2 SMA MNs relative to Hb9 control MNs.
URA also predicted that the effects of 5 drugs would be
inhibited in A2 SMA MNs as compared to Hb9 control MNs
(Figure 8C). The drugs identified were troglitazone (a PPARc
agonist), vorinostat (suberoylanilide hydroxamic acid (SAHA), a
histone deacetylase inhibitor), nicotine (acetylcholine receptor
agonist), decitabine (59-aza-29-deoxycytidine, a DNA methyltransferase inhibitor) and the inflammatory mediator lipopolysaccharide (LPS).

Validation of Differentially Expressed Transcripts
Identified by RNA-Seq
As a first step toward the validation of the RNA-Seq data, we
needed to reduce the number of differentially expressed transcripts
to a more manageable list. The initial list of differentially expressed
transcripts (using a p#0.05 as a criterion) was re-analyzed using
more stringent criteria. By filtering these data for differentially
expressed transcripts with a p-value less than or equal to 0.01 and
a greater than 4-fold change, the list of candidate transcripts was
reduced to 286 upregulated transcripts and 814 downregulated
genes. The filtering of these data was further refined so as to
include only those transcripts with a FPKM .30 (Figure 5B).
With this added refinement, there were 27 transcripts upregulated
in A2 SMA MNs and 220 downregulated transcripts.
To validate the results from the analysis of the RNA-Seq data,
we measured changes in the levels of selected differentially
expressed transcripts between Hb9 and A2 MNs by qRT-PCR.
We selected Smn1 since this gene is knocked out in SMA A2 cells.
In addition, six other transcripts were selected based on their
strong changes in transcript levels as shown by RNA-Seq: cellular
PLOS ONE | www.plosone.org

Differential Expression of Validated Transcripts in SMA
Mice
The levels of Smn1, Crabp1, Crabp2, Isl1, Nkx2.2, Pla2g1b and
Vim transcripts were examined in total RNA samples from control
(SMN2+/+;mSmn+/+) and severe SMA (SMN2+/+;mSmn2/2) mouse
spinal cords in order to determine if the changes observed in mESCderived MNs could also be observed in vivo. Mouse embryos of
similar genotypes were used to generate the mESCs used in this
study. Spinal cord total RNAs (n = 3/genotype) were extracted from
PND03 mice; severe SMA mice at this time point begin to show
signs of motor dysfunction [34]. Similar to SMA mESC-derived
10
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Figure 7. Functionally regulated gene networks in mESC-derived A2 SMA and Hb9 control MNs. The highest scoring interactomes
generated by IPA from the (A) upregulated or (B) downregulated transcripts in A2 SMA MNs when compared against Hb9 control MNs. Each node
represents a gene product in the network. Upregulated gene products are shown in red while the downregulated gene products are shown in green;
the intensity of color indicates the degree of regulation. The uncolored nodes represent unregulated gene products which have a relationship with a
colored node based on the literature. A line between two nodes represents a biological relationship with the line length indicating the amount of
literature-based evidence supporting this relationship. The solid lines represent direct interactions while the dashed lines represent indirect
interactions.
doi:10.1371/journal.pone.0106818.g007

MNs in culture, Smn1, Crabp1, Crabp2 and Nkx2.2 transcript
levels were reduced while Pla2g1b levels were increased in SMA
spinal cords (Figure 10A). Surprisingly, Isl1 and Vim mRNA levels
were elevated in SMA spinal cords at PND03 even though these
transcripts were reduced in SMA MNs. The samples isolated from
SMA mouse spinal cords contain RNAs from many different types
of neurons aside from MNs as well as other cell types such as
astrocytes and oligodendrocytes. This sample heterogeneity could
explain the discrepancies observed between mESC-derived SMA
MNs and SMA spinal cords.
Increasing SMN2 copy numbers can improve the phenotype
and survival of severe SMA mice [34,36]. In fact, SMN2
transgenic SMA mice with 8 (SMN2(566)+/2;mSmn2/2) or 16
copies (SMN2(566)+/+;mSmn2/2) of the transgene display no
motor phenotype [34]; in other words, the SMA phenotype is
rescued. When comparing relative changes in Smn1, Crabp1,
Crabp2, Isl1, Nkx2.2, Pla2g1b and Vim transcript levels in lowcopy SMN2 SMA mice with those observed in high-copy SMN2
rescue mice at PND03, the relative changes in each of these
transcripts—except for Smn1—were increased in high-copy rescue
mice as opposed to relative changes in low-copy SMN2 SMA mice
(Figure 10A). Smn1 mRNA levels were still reduced in high-copy
SMN2 rescue mice since these mice are still nullizygous for mSmn.
We also wanted to determine if the changes observed in severe
SMA mouse spinal cords are regulated developmentally. The
levels of Smn1, Crabp1, Crabp2, Isl1, Nkx2.2, Pla2g1b and Vim
transcripts were measured in severe SMA mice at embryonic day
13.5 (e13.5) relative to age-matched control littermates. There are
no overt changes in physical characteristics or in motor neuron
growth in SMA mice at this developmental age [45]. Smn1
mRNA levels were marked reduced in the embryonic SMA mouse
spinal cord as they were at PND03 (Figure 10B). Some
transcripts, like Isl1, Pla2g1b and Vim, showed reduced mRNA
levels at e13.5 even though the levels of these transcripts were
increased at PND03. The reductions in Crabp2 and Nkx2.2
transcripts were more pronounced at e13.5 than at PND03. These
results suggest that the changes in RNA expression of some
transcripts may be developmentally regulated in SMA.

Discussion
In this study, we compared the RNA expression profiles
(transcriptomes) between SMA and normal MNs in order to
identify the molecular consequences of SMN deficiency in these
cells. This study is the first to examine the transcriptome profiles of
isolated MNs derived from severe SMA and normal mESCs.
Differential gene expression studies using cDNA microarrays have
also been previously completed using primary MN cultures from
mSmn+/2 mice—a supposed model for mild SMA [61]—and
whole spinal cords from the SMA mouse models [40–42]. As
mentioned earlier, analysis of transcriptome profiling using RNASeq is advantageous because of the high signal-to-noise ratio,
independence from hybridization efficiency between probes and
targets and identification of novel RNA transcripts. In addition to
mouse models for SMA, differential transcriptome expression
analyses have been completed on other animal models of Smn
PLOS ONE | www.plosone.org

Figure 8. Upstream regulator analysis of differentially expressed transcripts between mESC-derived Hb9 control and A2
SMA MNs. IPA of significantly modified upstream (A) transcriptional
regulator, (B) endogenous signaling and (C) drug pathways in
upregulated or downregulated transcripts in A2 SMA MNs compared
to Hb9 control MNs. Significant upstream regulators were identified as
those having an activation z-score greater than or equal to 2.0 for
activated regulators or less than or equal to 22.0 for inhibited
regulators.
doi:10.1371/journal.pone.0106818.g008
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deficiency [62,63]. Recently, Zhang et al. [64] used RNA-Seq to
identify differentially expressed mRNAs in PND01 SMND7 SMA
mouse MNs isolated by laser capture microdissection (LCM). Our
study examines the transcriptome in purified, cultured MNs
derived from control and severe SMA mESCs. Using this model,
we can examine changes in RNA expression in a nearly
homogeneous population of cells which is not possible with
LCM.An advantage of using MNs derived from mESCs to
compare the transcript profiles of SMA MNs to normal MNs is
that large numbers of cells can be directed to differentiate into
MNs. This scalability can overcome two obstacles of using primary
MN cultures from SMA mouse spinal cords, low yield of MNs
from SMA mouse embryos and the fragility of these affected MNs.

Numerous studies in mice and zebrafish have shown that SMA
MNs are affected in a cell autonomous manner [26,65–67] which
would suggest that examining the transcriptome profiles of isolated
SMA MNs could provide relevant information on the pathobiology of this disease. In isolated mESC-derived SMA MNs, the
transcriptomes will not show the effects of target (i.e. skeletal
muscle) innervation and trophic signaling from skeletal muscle,
sensory neurons or glia. Future experiments will compare the
transcriptomes of mESC-derived SMA MNs grown in isolation
with those grown in the presence of myotubes and/or glial cells so
as to determine those gene regulatory events which are intrinsic to
SMA MNs (i.e. those grown in isolation) and those which are
dependent on environmental cues (i.e. those grown in the presence
of target or support cells).
MNs are the primary cells affected by reduced SMN expression
in SMA. Ectopic overexpression of SMN in the neurons of severe
SMA mice rescues the primary disease phenotype in these mice
while transgenic overexpression of SMN in mature skeletal muscle
does not improve the SMA phenotype [68]. Conditional
expression of SMN in the developing MNs of SMA mice—using
either the Hb9 or Olig2 promoters as drivers—significantly
ameliorates the SMA phenotype [65–67]. Martinez et al. [66]
also show that conditional expression of SMN in SMA skeletal
muscle may help grow and maintain muscle independent of MNs.
Increasing SMN expression outside of the nervous system with
either splice-switching oligonucleotides [69] or adeno-associated
virus (AAV) vectors [70,71] markedly improves the phenotype and
survival of SMA mice. These studies suggest that comparative
analysis of SMA MN transcriptomes from these models may
provide limited insight into the pathobiology of SMA; however, it
is appropriate to examine the transcript profiles of isolated SMA
MNs since they are affected in a cell autonomous fashion [26,65–
67].
The copy number of SMN2 modifies the severity of the SMA in
humans [13–20]. SMN2 also acts as a phenotypic modifier in
transgenic mouse models for SMA [34–36]. Increasing SMN
expression in MNs in vivo by pharmacological induction of SMN2
expression [72–74] or SMN gene replacement therapies
[70,71,75–77] improves the phenotype and survival of SMA
mice. The levels of certain mRNA transcripts such as Crabp1,
Crabp2 and Nkx2.2 were elevated in high copy SMN2 rescue
mice even though the levels of these transcripts were reduced in
low copy SMN2 severe SMA mice (Figure 10A). Increasing
SMN2 expression rescues molecular phenotype of Smn-deficient
MNs in vivo.
Many of the biological pathways and networks that were
overrepresented in those transcripts upregulated in A2 SMA MNs
involved ESC pluripotency (Figures 6A and 6C). The transcription factors Nanog, Pou5f1 (Oct4), and Sox2 are considered to be
hallmarks of ESC pluripotency [78]. mRNA transcripts for all
three of these factors were upregulated in SMA mESC-derived
MNs (Figure 6E). UPA of the differentially expressed transcripts
revealed that these three pluripotency transcription factors were
activated in A2 SMA mESC-derived MNs (Figure 8A). Several
gene products work with these three transcription factors to
regulate pluripotency in ESCs. Klf2 regulates the expression of
Sox2 [79]. Klf2 transcript levels were increased in SMA mESCderived MNs by 2.3-fold (Table S1). Zic3—whose transcript
levels were increased 3.1-fold in SMA mESC-derived MNs—is
directly regulated by all three transcription factors [80]. Zscan10
(also known as Zfp206), whose mRNA levels are elevated by 2.5fold in SMA mESC-derived MNs (Table S1), helps maintain
pluripotency by jointly functioning with Sox2 and Oct4 [81]. In
SMA mESC-derived MNs, the pluripotency marker Dppa5 (also

Figure 9. Validation of differentially expressed transcripts
determined by RNA-Seq using qRT-PCR. The levels of Crabp1,
Crabp2, Isl1, Nkx2.2, Pla2g1b, Smn1 and Vim transcripts were measured
in total RNAs from control and SMA mESC-derived MNs. (A) The
magnitude of change (log2(fold change)) of selected transcripts in A2
SMA MNs relative to Hb9 control MNs (n = 3/genotype) as determined
by RNA-Seq (black bars) or qRT-PCR (grey bars). (B) The magnitude of
change of selected transcripts in HB9:eGFP-labeled (black bars) or
unlabeled (grey bars) SMA MNs (A2 and E2 cells, respectively) relative to
control MNs (Hb9 and C4 cells, respectively; n = 3/genotype).
doi:10.1371/journal.pone.0106818.g009
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Table 3. Relationship between changes in mRNA levels measured by RNA-Seq and protein levels measured by 2D-DIGE or
immunoblot (*) of selected genes in normal versus SMA mESC-derived motor neurons.

Gene Symbol

Protein Name

mRNA Fold Change

Protein Fold Change

Cdkn1a

p21

20.764

+41.3*

Ldhb

lactate dehydrogenase B

+1.08

+3.60

Ckb

brain creatine kinase

N.S.

+1.80

Glo1

glyoxalase 1

20.970

+1.75

Tpm3

tropomyosin 3

N.S.

+1.75

Anxa5

annexin A5

20.487

+1.70

Uchl1

ubiquitin C-terminal hydroxylase L1

N.S.

+1.70

Tuba1a

a-tubulin

22.37

+1.50

Upregulated proteins

Downregulated proteins
Aldh5a1

aldehyde dehydrogenase

20.952

21.70

Ywhag

14-3-3c

N.S.

21.70

Hsp90b1

Heat shock protein 90b

N.S.

21.80

Hspa9

Heat shock protein 70

+0.812

22.20

The protein expression data is taken from [46].
doi:10.1371/journal.pone.0106818.t003

known as ESG-1 [82]) transcript levels were increased by 1.2 fold
(Table S1). The levels of Dppa5 mRNA are significantly
upregulated—as shown with microarray analysis—in the presymptomatic severe SMA mouse spinal cord [42]. Two genes that
are also implicated in the maintenance of pluripotency—Mybl2
and Zfp42 (Rex1) [83,84]—were upregulated by 2.2- and 2.8-fold,
respectively, in SMA mESC-derived MNs (Table S1).
Neuronal development and activity functions are impaired in
A2 SMA mESC-derived MNs given that these biological pathways
and networks were overrepresented in the downregulated RNA
transcripts (Figures 6B and 6D). Vimentin (Vim) is an
intermediate filament protein that is transiently expressed by all
neuronal precursors. It may have a role in neurite outgrowth in
developing hippocampal neurons [85]. Nkx2.2 is homeobox
transcription factor which is activated downstream of Shh; it has
a primary role in ventral neuronal patterning and in generating
interneurons [86]. Islet1 (Isl1) and Olig2 are transcription factors
expressed during and are necessary for MN development [37].
Vim, Nkx2.2 and Isl1 mRNA levels were markedly reduced in
mESC-derived SMA MNs (Figure 9) and in e13.5 SMA mouse
spinal cords (Figure 10); Olig2 mRNA levels were reduced by
5.5-fold in A2 SMA mESC-derived MNs (Table S1). Using
microarray analysis, the expression of neurexin2a (nrxn2a) is
downregulated in zebrafish embryos with reduced smn expression
[63]. Nrxn2a transcript levels are also reduced in the spinal cord
of severe SMA mice [63]. Nrxn2 deficiency has been implicated in
altered neuronal excitability. We found that Nrxn2a mRNA levels
were reduced by 2.9-fold in SMA mESC-derived MNs (Table
S1).
The Notch pathway, via cell-cell interactions, stimulates neural
precursors cells to differentiate into neurons and glial cells [87].
Notch pathway signaling was the top canonical pathway
overrepresented in the list of transcripts downregulated in A2
SMA mESC-derived MNs (Figure 6D). Many of the components
of this pathway including Notch as well as its extracellular ligands
Jagged and Delta were reduced in A2 SMA mESC-derived MNs
(Figure 6F). Neurogenin-3 (Neurog3) mRNA levels were reduced
by 1.3-fold in SMA mESC-derived MNs (Table S1) and Neurog3
PLOS ONE | www.plosone.org

was identified as one of the inhibited transcription factor activities
in the UPA (Figure 8A). These results are surprising given that
Notch protein immunolocalization is increased on the ventral horn
motor neurons of SMND7 SMA mice at PND11 [88]. Jagged1
and Delta1 protein immunolocalization is also increased on
adjoining astrocytes in these mice. The differences between our
observations and those of Carabello-Miralles et al. [88] could be
the result of different SMA models being used (low copy SMN2
severe SMA vs. SMND7 SMA) or types of gene regulation being
examined (transcription vs. translation). Cell-cell interactions
between neurons and glia that regulate the expression of Notch
signaling ligands and receptors may not be apparent in our model
system (purified MNs in culture); however, both studies document
reduced Neurog3 expression and activity in SMA MNs ([88] and
this work).
RA is known for driving cellular differentiation and has a
neuralizing effect during neuronal development. UPA of the
differentially expressed transcripts in A2 SMA mESC-derived
MNs showed that all trans-RA (tretinoin) signaling was inhibited in
SMA MNs (Figure 8B). Transcripts whose protein products are
involved in RA signaling and metabolism were downregulated in
A2 SMA mESC-derived MNs. Cellular retinol-binding protein
(Rbp1) and the cellular RA binding proteins Crabp1 and Crabp2
are expressed in early mouse embryos and may play a role in the
development of the CNS [89,90]. The expression of the
pluripotency-related protein Zfp42 (Rex1)—whose mRNA was
upregulated in A2 SMA mESC-derived MNs, as mentioned
earlier—is repressed by RA in F9 teratocarcinoma cells [91].
Rbp1, Crabp1 and Crabp2 mRNA levels were reduced in SMA
mESC-derived MNs (Figure 9 and Table S1) as well as in severe
SMA spinal cords (Figure 10). Microarray analysis of PND05
(late-symptomatic) severe SMA spinal cord mRNAs also identify
impairments in RA signaling and metabolism [42]. RA regulates
many phases during MN differentiation [92]. RA has been
implicated in its ability to induce neurogenesis by blocking
fibroblast growth factor (FGF) signaling [93]. Furthermore, RA
and FGF signaling are sufficient to induce MN differentiation
independent of Shh signaling [94].
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proteins found in MNs—like choline acetyltransferase (ChAT),
HB9 and neurofilament—are not altered by SMN deficiency [46].
Taken together, our observations suggest that SMA MNs can
initially develop normally but they do exhibit changes in
transcripts related to pluripotency and neural development. These
transcripts may have novel functions in MNs aside from
development.
Microarray analysis of differential gene expression between
control and severe SMA spinal cord transcript pools suggest that
SMA is a neurodegenerative disease instead of a neurodevelopmental disorder [42]. We did not observe an overrepresentation of
apoptosis and cell death transcripts in the pathway and network
analyses of our differentially expressed transcriptome data. There
is no noticeable cell death in the ventral horn of the spinal cord of
severe SMA mouse embryos even though cell death can be
detected in the telencephalon [95]. When A2 SMA mESC-derived
MNs were plated onto coverslips, we did observe a timedependent loss of cell viability and reduced neurite outgrowth
(Figure 4). Similar reduced neurite outgrowth and cell death are
observed in MNs differentiated from induced pluripotent stem cell
(iPSC) lines derived from human SMA fibroblasts [96–99].
Primary MNs cultured from severe SMA mouse embryos exhibit
reduced neurite lengths [30]. Knockdown of Smn in zebrafish
embryos with morpholino antisense oligonucleotides results in
defects in motor axons suggesting early developmental defects
[26]. We found that many of the biological pathways downregulated in A2 SMA mESC-derived MNs involved axonal guidance
(Figure 6D). No developmental defects in motor axon formation
occur in severe SMA mice [26,95]. In both mouse and fruit fly
models for SMA, the maturation and maintenance of neuromuscular junctions is defective and this defect may be the result of
denervation injury and/or neurodevelopmental delay [45,100–
103]. Comparison of presymptomatic control and SMND7 SMA
MNs using RNA-Seq reveal deficits in transcripts related to
synaptogenesis including agrin (Agrn) [64]. In our isolated mESCderived SMA MNs, we also observed a significant (0.85-fold)
decrease in Agrn mRNA levels (Table S1). Our transcriptome
analysis suggests that there may be neurodevelopmental delays in
SMA MNs; however, SMA MNs develop normally initially and
form connections with target muscles but these connections then
atrophy for unknown reasons (reviewed in [21]). Upregulation of
pluripotency and cell proliferation transcripts as well downregulation of neuronal development-related transcripts in SMA MNs
may be a consequence of denervation and axonal degeneration.
In conclusion, we have identified distinct gene expression
patterns in SMA MNs when compared to normal MNs. Pathways
upregulated in SMA mESC-derived MNs were involved in
pluripotency and cell proliferation whereas common pathways
found in the downregulated genes have shown decreases in
neuronal markers commonly found in mature and developing
neurons. It remains to be determined whether these neuronal
marker deficits are a contributing cause or a consequence of the
disease. The mechanisms underlying these changes in the
transcriptome of SMA MNs will need to be examined in more
detail for future studies. Comparison of SMA MN transcriptomes
against normal MN RNA transcript profiles will also lead to the
identification of novel targets for the development of therapeutics
for SMA.

Figure 10. Expression of RNA-Seq-identified differentially
expressed transcripts in SMA mouse spinal cords. The levels of
Crabp1, Crabp2, Isl1, Nkx2.2, Pla2g1b, Smn1 and Vim transcripts were
measured in spinal cord total RNAs from control and SMA mice. (A) The
magnitude of change (log2(fold change)) of selected transcripts in low
copy SMN2 SMA (SMN2(89)+/+;mSmn2/2; black bars) or high copy SMN2
rescue (SMN2(566)+/+;mSmn2/2; grey bars) mouse spinal cord samples
(n = 3/genotype) relative to control samples. (B) The magnitude of
change of selected transcripts in low copy SMN2 SMA mouse spinal
cord samples relative to controls at embryonic day 13.5 (e13.5; black
bars) and postnatal day 3 (PND03; grey bars).
doi:10.1371/journal.pone.0106818.g010

The upregulation of pluripotency-related transcripts and the
downregulation of transcripts related to neuronal development
and activity identified in this study suggest that SMA mESCs may
not be differentiating into MNs as efficiently as normal mESCs.
The difference between the number of MNs differentiated from
A2 SMA and Hb9 control mESCs was not significant (Figure 3).
This observation was based on eGFP expression that was driven
by the MN promoter HB9. HB9 is a late-stage MN marker [37].
Consistent with the FACS analysis, Hb9 mRNA expression was
not significantly altered in SMA mESC-derived MNs even though
the mRNA levels for early-stage MN markers like Isl1 and Olig2
were reduced in A2 SMA mESC-derived MNs. The levels of
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Table S1 List of all of the annotated RNA transcripts
that are differentially expressed in A2 SMA mESC-
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